We aim to characterize work exposures and illness in Badin, North Carolina--the site of an aluminum smelting facility for nearly 100 years.

The overall objective of this project is to examine differences in performance fatigability and contributing mechanisms between firefighters in cancer remission and healthy firefighter controls. Findings from this research project will inform future interventions to reduce CRF in firefighters in cancer remission.

To comprehensively characterize the clinical, laboratory, and histopathologic features of breast cancer patients receiving care according to local standards in Malawi.

To evaluate whether different biomarkers can stratify patients with newly diagnosed GBM that have progressive enhancement within 12 weeks post-XRT into risk groups based on overall survival.

The purpose of this research study is to learn more about Barrett's Esophagus and esophageal cancer by collecting data and samples (blood and tissue) for a biorepository. A biorepository is a large bank of specimens and data that are stored indefinitely and may be shared with other researchers.

The purpose of this study is to measure the effect of 30 mg RE104 on adjustment disorder symptoms (depressed mood or anxiety) compared to 1.5 mg RE104 in participants with cancer or other illnesses in order to decrease these symptoms.

We have created a workbook about Lynch Syndrome, a genetic condition that means an individual is at high risk of developing certain cancers, and family testing. It is important that patients with Lynch Syndrome tell their family members about their condition so their family members understand their risks and can be tested for Lynch Syndrome too. We are testing our workbook with a small group of patients with Lynch Syndrome to understand if the workbook is helpful in managing their condition and talking to family members.

This phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better compared to crizotinib and standard therapy alone in treating younger patients with neuroblastoma or ganglioneuroblastoma.

Ovarian cancer is the second most frequently diagnosed gynecologic cancer in the United States. Although it is the eleventh most common cancer among women, ovarian cancer is the fifth leading cause of cancer-related death. Fortunately, survival rates for ovarian cancer patients have been improving over the past few decades due to advances in medical procedures and the availability of new cancer drugs. However, studies have shown that the improvement of clinical outcomes are unequal among patients of different racial and ethnic backgrounds. This study seeks to understand the factors associated with healthcare disparities in Black ovarian cancer patients and identify features of programs that have been successful in addressing these racial imbalances. The findings of this study will help the researcher develop future programs to address healthcare disparities in Black ovarian cancer patients.

Screening tool to collect broader demographic and clinical data. Enhance understanding of site specific and trial specific accrual barriers.